Stroke

FOCUSED UPDATES

Cerebral Small Vessel Disease–Related Dementia: More Questions Than Answers

Fanny M. Elahi, MD, PhD; Michael M. Wang, MD, PhD; James F. Meschia, MD

ABSTRACT: Cerebral small vessel disease (CSVD) has emerged as a common factor driving age-dependent diseases, including stroke and dementia. CSVD-related dementia will affect a growing fraction of the aging population, requiring improved recognition, understanding, and treatments. This review describes evolving criteria and imaging biomarkers for the diagnosis of CSVD-related dementia. We describe diagnostic challenges, particularly in the context of mixed pathologies and the absence of highly effective biomarkers for CSVD-related dementia. We review evidence regarding CSVD as a risk factor for developing neurodegenerative disease and potential mechanisms by which CSVD leads to progressive brain injury. Finally, we summarize recent studies on the effects of major classes of cardiovascular medicines relevant to CSVD-related cognitive impairment. Although many key questions remain, the increased attention to CSVD has resulted in a sharper vision for what will be needed to meet the upcoming challenges imposed by this disease.

GRAPHIC ABSTRACT: A graphic abstract is available for this article.

Key Words: Alzheimer disease ■ biomarker ■ blood-brain barrier ■ dementia ■ magnetic resonance imaging

The broad term cerebral small vessel disease (CSVD) describes heterogeneous conditions affecting blood vessels of 50 to 500 µm in diameter. Multiple distinct pathologies can cause CSVD, most commonly hypertensive vasculopathy and cerebral amyloid angiopathy. The clinical challenge is that rarely are there indications for obtaining tissue for a definitive diagnosis. Neuroimaging, however, is readily available, and standards exist for using imaging to diagnose CVSD[1] (Figure 1). The STRIVE (Standards for Reporting Vascular Changes on Euroimaging) group proposed standardized terminology and suggested minimum standards for imaging suspected CSVD, though imaging technology continues to evolve. Current and future standards for CSVD diagnosis will certainly depend on feasible, reliable, and quantitative neuroimaging.

See related article, pages 646, 661, 673, 686

CSVD can manifest as symptomatic cerebral hemorrhages, small ischemic strokes, and cognitive impairment. Symptomatic hemorrhages are easily recognized and diagnosed. Small ischemic strokes are also easy to recognize, but small strokes from CSVD must be distinguished from strokes due to small emboli. Thus, even when pretest probability is high, neuroimaging is essential for diagnosing CSVD.

Diverse CSVD markers seen on magnetic resonance imaging (MRI; Figure 1) correlate in aggregate with cognitive and functional decline.[2] Findings such as white matter hyperintensity raise suspicion for CSVD. Additional imaging findings with greater specificity but unknown sensitivity for CSVD include enlarged perivascular spaces,[3] abnormal diffusion measures,[4] and blood-brain barrier (BBB) leakage seen with dynamic contrast-enhanced MRI.[5] Other lesions, such as recent small subcortical infarcts, lacunae of vascular origin, and microbleeds are the most specific, clinically available CSVD biomarkers.

CSVD-related dementia is a major subgroup within vascular cognitive impairment and dementia (VCID). VCID is a challenging disorder to ascertain, prompting numerous

Correspondence to: Michael M. Wang, MD, PhD, Departments of Neurology and Molecular and Integrative Physiology, University of Michigan, VA Ann Arbor Healthcare System, 2215 Fuller Rd, Bldg 31-221, Ann Arbor, MI 48105. Email micwang@umich.edu
For Sources of Funding and Disclosures, see page 657.

Stroke is available at www.ahajournals.org/journal/str

groups to evaluate diagnostic criteria to make the diagnosis more reliable and enable cross-study comparisons. A comparison of 5 major diagnostic criteria for vascular dementia applied to consecutive ischemic stroke patients followed for 3 months with MRI and cognitive testing found wide variability in the prevalence of vascular dementia depending on criteria used from 32.7% (Alzheimer's Disease Diagnostic and Treatment Centers criteria) to 91.6% (*International Statistical Classification of Diseases and Related Health Problems Version 10* criteria).[6] The same study found that only 37.4% of patients had focal neurological deficits at 3 months, highlighting the importance of imaging to detect cerebrovascular disease.

The limited clinicopathological studies of VCID highlight the challenges of making a premortem diagnosis that correlates well with pathology. An autopsy study of 89 patients with dementia found no statistically significant relationship between a neuropathological diagnosis of vascular dementia and any of 3 clinical criteria (*International Statistical Classification of Diseases and Related Health Problems Version 10*, Alzheimer's Disease Diagnostic and Treatment Centers, and National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche et l'Enseignement en Neurosciences).[7] Another challenge is that there is no agreed-upon histopathological diagnosis for VCID,[8] though commonly cited features of CSVD include wall thickening, vascular cell loss, and laminar protein accumulation (Figure 2). Ongoing studies correlating imaging with pathology should help in making reliable premortem diagnosis of clinically significant CSVD.[9]

CSVD-related dementia is thus in a state of evolution: although well-recognized as an important entity, many improvements in understanding await. Since many excellent discussions have already been presented, this review focuses on 5 common questions.

MY PATIENT HAS CSVD: WILL IT CAUSE DEMENTIA?

CSVD does not always lead to dementia or even cognitive impairment. In routine practice, MRI obtained for a variety of concerns in cognitively normal middle-aged or older individuals will frequently demonstrate findings associated with CSVD. Although the presence of CSVD does not ensure dementia, there appears to be a strong correlation between CSVD and development of dementia in diverse populations. The best evidence of this is provided by longitudinal studies. At least 20 studies[10–21] have investigated white matter hyperintensities and incident dementia that, in large part, include European and North American populations; 2 studies of these investigations were performed in East Asia.

A meta-analysis of studies over the last 2 decades by Debette et al[22] places the hazard ratio imposed by CSVD as 1.84 (P<0.001; over 9338 study subjects); the total incidence of dementia among these subjects was 12%, though the length of observation for each of the studies varied significantly. Two separate overlapping meta-analyses by Rensma et al[23] and Bos et al[24] concluded that white matter hyperintensities presented a significant risk of incident dementia. As such, the pragmatic counseling for patients found to have CSVD is that this condition does not always cause dementia but that it substantially increases the risk.

Although in practice these principles are applied broadly, current studies do not adequately cover all ethnicities and races. It is also not known whether there are other clinical characteristics, combinations of risk factors, or genetic determinants that render CSVD deterministic in some individuals.

Because CSVD is associated with several abnormalities on MRI, there could be subtypes of sporadic age-related CSVD.[25] One question that has emerged is whether specific MRI markers of CSVD could be useful in prognostication of dementia. Debette et al[22] analyzed several CSVD features for as predictors of dementia. Although white matter hyperintensities were clearly associated with increased risk of incident dementia, subcortical brain infarcts or cerebral microbleeds did not reach significance, despite the size of the aggregate study population (8736 individuals). Rensma[23] and Bos[24] found that dementia was increased or borderline significant in studies of patients with lacunar infarcts but not microbleeds. The ability to compare these MRI findings is limited because most studies lacked direct comparison of MRI features. Studies of perivascular spaces have reported increased incident dementia risk in a small number of studies.[26,27]

MY PATIENT HAS DEMENTIA: IS THIS CSVD-RELATED DEMENTIA?

In dementia, especially late-life sporadic disease, definite diagnoses are based on neuropathological examination only available at autopsy.[28,29] Marching back from that, select in vivo biomarkers, such as AD Amyloid/Tau/Neurodegeneration biomarkers, aid in premortem diagnoses with high confidence. In contrast, outside of monogenic causes of VCID, cognitive impairment due to CSVD faces diagnostic obstacles. The first problem is lack of clear neuropathological consensus criteria. The second is the scarcity of sensitive and specific in vivo biomarkers for CSVD-related VCID. The third is lack of distinct clinical syndromes for VCID. The fourth is the variable lag between diagnosis of vascular risk factors or vascular disease and onset of cognitive and neurobehavioral symptoms, diminishing the power of predictive models with limited longitudinal follow-up.

In postmortem analyses of individuals with dementia, vascular disease, especially CSVD lesions and tissue



Figure 1. Neuroimaging in cerebral small vessel disease–vascular cognitive impairment and dementia. **A**, Subcortical and periventricular white matter hyperintensities on T2/fluid-attenuated inversion recovery (FLAIR) sequences. **B**, Lacunar stroke a cavity with a rim of hyperintensity on FLAIR. **C**, Enlarged perivascular spaces on T1 sequence, can appear both as streak-like spaces as well as punctate. **D**, Subcortical microhemorrhages on T2* susceptibility-weighted imaging (SWI) sequence. **E**, Cortical microhemorrhages on T2* SWI sequence. **F**, Superficial siderosis on T2* SWI sequence.

abnormalities, such as microinfarcts, microbleeds, and arteriolosclerosis, have been noted as common pathologies and co-pathologies, increasing the odds of dementia in the aging brain.[30] The challenge, however, has been in attributing the cause of premortem dementia to CSVD, especially in the setting of quantifiable nonvascular neurodegenerative diseases.[31]

The likelihood of causal assignment of cognitive impairment to vascular disease is further decreased in the setting of coexisting nonvascular neurodegenerative disease syndromes that have syndromic presentations or biomarkers (eg, Alzheimer disease [AD]).[29] This in part is due to lack of clear clinical syndromes associated with CSVD and, critically, a lack of highly accurate CSVD in vivo biomarkers. For example, in AD, postmortem analyses have demonstrated that 80% to 100% of individuals with parenchymal amyloid plaques have cerebral amyloid angiopathy. When cerebral amyloid angiopathy is significant, especially in *APOE4* carriers, cortical microbleeds can be seen in brain imaging. These microbleeds can be seen before significant cognitive and functional impairment, and in some instances are the first imaging abnormality noted for a patient who may also demonstrate white matter hyperintensities, arteriolosclerosis, and lipohyalinosis.[32] Even so, attribution of brain dysfunction to AD in patients with mixed AD and CSVD has traditionally underestimated vascular contributions.

AD has several clinical syndromes such as the typical amnestic-predominant or limbic AD, behavioral-executive AD, posterior cortical atrophy, and logopenic variant primary progressive aphasia. The syndromic presentations of these variants are assumed to be nonvascular, but the prevalence of cerebral amyloid angiopathy is thought to be similar across AD syndromes; thus, in such syndromes, the vascular contribution to dementia deserves more investigation. Outside of AD, additional clinical syndromes, such as frontotemporal dementias and Lewy body disorders are considered nonvascular neurodegenerative diseases. The prevalence of CSVD in these syndromes remains understudied. Yet, CSVD affects white matter and brain connectivity, causing cognitive speed and executive function decline which are common to nonvascular disorders and CVSD. Symmetric parkinsonism is another clinical symptom that could be due to subcortical CSVD. These motor manifestations are also not sufficiently specific enough to point the diagnostic compass toward VCID.

Teasing apart diverse CSVD contributions to clinical symptoms would require in vivo molecular biomarkers that are not currently available. MRI-apparent CSVD lesions, detailed above, are unlikely to be the earliest manifestations of disease. Moreover, none have been demonstrated to be both sensitive (as an early abnormality) and specific (capturing disease of vasculature rather than neuro-glial degeneration). Importantly, dysfunction of the BBB (discussed below), measured by dynamic contrast-enhanced MRI as well as with cerebral spinal fluid/serum albumin quotient, is an uncommonly assessed parameter in practice and research, though recent studies suggesting a potentially early causal association with brain dysfunction and degeneration.

Notwithstanding, according to the 2020 Lancet Commission's Report on Dementia Prevention, Intervention, and Care, up to 40% of dementia worldwide are preventable.[33] Many of these modifiable risk factors either directly or indirectly fall under the rubric of vascular

 Stroke. 2023;54:648–660. DOI: 10.1161/STROKEAHA.122.038265



Figure 2. Histopathological features of cerebral small vessel disease (CSVD).
Common histopathological features include arterial wall thickening, vascular cell loss, and protein accumulation in a laminar pattern. The top photo shows a normal-appearing white matter artery stained with hematoxylin and eosin (H&E). The middle row shows markedly thickened small arteries in a patient with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), an inherited CSVD. On the **left** is a vessel after Miller staining, which shows massive vessel thickening and fraying elastin fibers of the intimal/medial function. Cell loss is demonstrated in the H&E-stained CADASIL artery on the **right**. The **lower** part illustrates layered protein accumulation in a patient with CADASIL. The **left** photo shows staining for all collagens using a collagen-binding peptide probe that stains all 3 layers of the vessel (adventitia, media, and intima). The **middle** photo shows staining with a NOTCH3 neo-epitope antibody that principally highlights the media; in cerebral amyloid angiopathy, the media accumulates Aβ. The **right** photo shows staining for COL4A that localizes predominantly to the intima. Scale bar span 40 microns for rows 1–2 and 100 microns for row 3.

disease. Therefore, CSVD is an important contributor to brain dysfunction and an ideal therapeutic target for cognitive impairment and dementia. Brain blood vessels have numerous roles, such as gating communication between peripheral organs, blood, and brain, interacting with immune cells and controlling entry and exit of molecules, and cells to and from the brain. In addition, a molecular cross-talk between blood vessel cells and neurons control steady-state perfusion as well as rapid on-demand increases in cerebral blood flow (CBF) to active neuronal networks.[34] Therefore, CSVD is a reasonable contributor to disorders of cognition.

In summary, in routine clinical practice, whether CSVD causes dementia in a particular patient is not easily answerable. Brain dysfunction frequently occurs in the setting of multiple pathologies. Current barriers to assignment of roles of CSVD in neuropsychiatric symptoms, motor dysfunction, and cognitive impairment include the need for better in vivo molecular and imaging biomarkers, methods to disentangle mixed vascular and nonvascular pathologies, and better clinical recognition of mechanisms connecting CSVD to brain dysfunction.

MY PATIENT HAS CSVD-RELATED DEMENTIA: WHAT IS THE DIFFERENTIAL DIAGNOSIS OF CSVD DEMENTIA?

Vascular risk factors and qualitative evaluations of small and large vessel diseases are considered treatable, potentially modifiable risk factors for neurodegenerative disorders. But the extent to which CSVD and other vasculopathies contribute to brain degeneration in each patient generally remains a matter of opinion and escapes a specific diagnosis. Monogenic vasculopathies are the exception to the diagnostic ambiguity regarding VCID. Clinical syndrome, family history, and imaging

biomarkers raise suspicion for a genetic cause of SVD-related dementia (Table 1), which genetic testing can confirm. Several are described below.

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), caused by *NOTCH3* mutations, is a uniquely pure form of CSVD that features insidious onset, gradually progressive neurobehavioral decline, chronic white matter disease (with involvement of anterior temporal lobes), lacunes, microbleeds, and migraines.[35] Less frequently, parkinsonism or seizures have also been reported.[36] Separate from CADASIL, *NOTCH3* mutation disease can present with either syndromic findings or lead to other neurological presentations[37]; *NOTCH3* mutations are also associated with AD[38] and Parkinson disease syndromes.[39] Recent studies indicate that up to 1:300 individuals carry mutations in *NOTCH3*.[40,41]

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy, an autosomal recessive disease related to mutations in *HTRA1*, presents with CSVD and non-neurological symptoms of alopecia, spondyloarthropathies, and changes in vision. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations affects mainly brain and retina and is caused by mutations in *TREX1*. A unique feature of retinal vasculopathy with cerebral leukoencephalopathy is that lesions may appear and behave like tumors.

Gould syndrome caused by mutations in *COL4A1* and *COL4A2* leads to defects in extracellular matrix, notably vascular basement membranes with multi-organ involvement including a characteristic CSVD, cerebral cortical developmental abnormalities, myopathy, renal and lung dysfunction, and marked ophthalmic abnormalities with developmental defects (ocular dysgenesis). Mutations in the 3' untranslated region of *COL4A1* mRNA can cause pontine autosomal dominant microangiopathy and leukoencephalopathy, characterized by early adult-onset pontine strokes.

Although these genetic CSVD syndromes can be confirmed easily using genetic testing, they are uncommon. Sporadic, age-dependent CSVD is by far the most common cause of this condition in the general population. But discoveries in rare genetic VCID syndromes could inform the mechanisms and therapy of sporadic disease.

WHAT IS THE BIOLOGICAL BASIS OF CSVD DEMENTIA?

Advanced morphological and molecular techniques have enabled a more nuanced understanding of the structural changes that result from CSVD. Furthermore, advanced imaging has enabled investigations in cross-sectional and longitudinal cohorts. Physiological studies of animal models of CSVD, modeling human genetic disorders, permit investigation of how CSVD leads to functional alterations of the brain that are presumed to cause dementia. What has emerged from these multidisciplinary studies are 3 core potential mechanisms by which CSVD leads to imaging changes—an imperfect proxy for dementia.

Decreased CBF

Lowering of overall blood flow in CSVD has been suggested as a mechanism driving dementia. It is reasoned that CSVD results in chronic hypoperfusion, particularly in watershed regions such as the deep white matter, which demonstrates the most severe MRI abnormalities. If true, one would expect lower CBF in patients with CSVD; moreover, lower blood flow should predict development of MRI changes and dementia.

The drop in global CBF in patients with CSVD has been observed in numerous populations in cross-sectional analyses,[42–48] although not universally.[49–51] Meta-analysis describes an association between low CBF and CSVD inferred by MRI.[49] In many studies in which blood flow dropped, the fall in flow was associated with atrophy, suggesting to some that flow changes were a result of tissue injury and not the cause of brain parenchymal damage. In longitudinal studies, there have been mixed results: some studies show CBF deficiency predicting MRI hyperintensities while others find falling CBF after development of lesions.[52–55] Further complicating the issue, regulation of flow may change at different stages of disease[56]; in early CSVD, resting CBF may increase, raising the possibility of shunting that may injure tissue.

Protein markers of hypoxia within white matter lesions have been presented[57] in a histopathological study of postmortem brain. But whether these markers presage the development of structural changes is not clear.

Alteration of the Blood-Brain Barrier

Other investigations have been presented that support CSVD causes brain parenchymal damage via changes in 2 vascular functions: (1) BBB integrity and (2) vasoreactivity determined by activity.

Structural abnormalities observed in CSVD can decrease BBB integrity. Pathological studies performed on autopsy-derived samples from patients with sporadic CSVD have shown extravasation of blood proteins.[58–63] The ultrastructural components of the BBB are affected in mice expressing NOTCH3 mutant protein.[64] In patients with CSVD,[65–70] BBB breakdown has been described in multiple cohorts. Longitudinal studies suggest that areas of BBB breakdown predict evolution of white matter hyperintensity.[71,72] The relative importance of specific substances that leak through the BBB to damage brain parenchyma remains an unknown, but serum proteins have been suspected to be harmful. For example, fibrinogen can cross a leaky BBB[58,60] and has multiple cellular

 Stroke. 2023;54:648–660. DOI: 10.1161/STROKEAHA.122.038265

Table 1. Monogenic CSVD Disorders

Syndrome	Gene	Mutation prevalence	Disease incidence	Clinical syndrome	Imaging	Pathological findings
CADASIL	*NOTCH3*	>230 mutations in 34 EGFR regions, >95% missense, mainly cysteine altering; cysteine-sparing mutations are less common	Classical syndrome: 2–5 in 100 000	Transient ischemic attacks and strokes, neuropsychiatric symptoms, cognitive impairment, apathy, mood disturbance including depression, rarely psychosis; migraine with or without aura; seizures (5%–10%)	Confluent WMH by fifth decade of life in anterior temporal lobes, external capsule, periventricular areas, centrum semiovale, superior frontal gyrus	Deposition of GOM adjacent to VSMCs caused by mutated *NOTCH3* ECD, containing other proteins
	Autosomal dominant		Mutations discovered 2.2 in 1000			Arteriopathy, most severe in small penetrating cerebral and leptomeningeal arteries
					Lacunar infarcts, enlarged perivascular spaces, cerebral microhemorrhages	Widespread cortical neuronal apoptosis
						Arterial wall thickening and
		Mutations lead to aggregation of *NOTCH3* ECD				fibrosis, stenosis
						Degeneration of VSMCs and pericytes
					Brain atrophy (late life)	Myelin degeneration
						Blood-brain barrier dysfunction
CARASIL	*HTRA1*	Missense and nonsense mutations, and a few compound heterozygous individuals affecting protease activity of this serine protease	~5100 cases reported	Brain: ischemic strokes, cognitive decline and dementia by 30–40-year-old, gait disturbance	Symmetrical WMH in periventricular and deep WM, occasionally in anterior temporal lobes and external capsules	Loss of VSMCs
	Autosomal recessive (mainly)					Hyalinosis, fibrosis, and thickening of blood vessel walls
				Spine: lumbago (low back pain),		Thinning of cerebral arterioles ECM leading to enlargement, loss of vascular elasticity and collapse
				Hair: alopecia (hair loss)	Notable hyperintense arc from pons to middle cerebellar peduncle in late disease stages.	
				Heterozygous HTRA1 CSVD has milder presentation without extra-CNS symptoms, and some HTRA1 mutation carriers can be asymptomatic		
					Lacunar infarcts in basal ganglia and thalamus,	
					Cerebral microhemorrhages	
					Herniated lumbar and cervical disks with degeneration	
					Brain atrophy	
Gould syndrome	*COL4A1/2*	Missense mutations mainly in highly conserved glycine residues in the triple helical domain of the *COL4A1* gene. Other mutations impairing translation; insertions also reported.		Highly variable multisystem disease	White matter disease, lacunar infarcts, intracranial aneurysms of carotid siphon even in asymptomatic	Intracellular and extracellular accumulation of defective collagen in vessel walls, small vessel fragility, and barrier dysfunction
	Autosomal dominant			BBB dysfunction and recurrent subcortical hemorrhages. Disease affects brain, spinal cord, eye, muscles, and kidneys.	PADMAL: lacunar infarcts of BG, brain stem, pons, and periventricular, pyramidal tract degeneration	
				Brain: cerebral SVD, cerebral aneurysms, stroke (hemorrhagic and ischemic).		
		Mutations in the 3' untranslated region of COL4A1 cause PADMAL.		Eye: retinal arterial tortuosity, cataract, developmental microphthalmia, and Axenfeld-Rieger syndrome		
				Other affected organs: kidney, anemia, muscular cramps, cardiac arrhythmias, and Raynaud		Basement membrane instability
				PADMAL: dysarthria, ataxia, paresis, mood disturbance, gait abnormality, stroke, and dementia.		PADMAL: proliferation of intima, increased elastic fibers, atrophy of tunica media of arterioles

(*Continued*)

Table 1. Continued

Syndrome	Gene	Mutation prevalence	Disease incidence	Clinical syndrome	Imaging	Pathological findings
RVCL-S	*TREX1* Autosomal dominant	C-terminal frameshift mutations, mislocalization, immune dysfunction	Exceedingly rare (<100 families known)	Brain capillary rarefaction, strokes, tumor-like lesions, proteinuria, hematuria, macular edema with perifoveal microangiopathic telangiectasias, migraines, psychiatric disturbances, possibly early death	Focal T2 hyperintense lesions (tumor-like in appearance) in periventricular and deep WM Contrast-enhanced pseudotumors focal calcifications visible before symptoms Frontal lobes heavily affected; corpus callosum and infratentorial tissue spared	Thicker and multilayered vascular basement membrane Vessels with fibrinoid vascular necrosis or thickened hyalinized walls
Fabry disease	*GLA* X-linked recessive	Insufficient activity of αGAL (early and late-onset depend on x-inactivation and other factors)	1 in 3100–117000	Neuropathy, angiokeratomas, hypohidrosis, corneal opacity, and hearing loss. Internal organs, such as the kidney, heart, or brain, may also be affected, leading to progressive kidney damage, heart attacks, and strokes (type 1 or early onset); diffuse white matter lesion with severe intracerebral hemorrhage and epilepsy can occur. Type 2 or late onset spears kidney and other organs	Deep WM lesions, T1 hyperintensities in pulvinar (thalamus) are pathognomic infarcts in posterior circulation and vertebrobasilar dolichoectasia microbleeds, lacunar infarcts	Accumulation of glycosphingolipids in ECs/VSMCs
Hereditary Cerebral Hemorrhage with Amyloidosis (HCHWA)	Dutch, Italian, Flemish, Iowa, and Piedmont types: *APP* Icelandic type: *CST3*	CAA associated disease	Rare			Misfolded Aβ 42 amyloid deposition in arteries, arterioles, capillaries and veins, and parenchyma, degeneration of VSMCs Icelandic: amyloid fibril deposition in cerebral arteries, lymphoid organs, skin, salivary glands, testes

APP indicates Aβ precursor protein; BG, basal ganglia; CAA, cerebral amyloid angiopathy; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CARASIL, cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy; CNS, central nervous system; COL4A1, collagen IV A1; CST3, cystatin C 3; CSVD, cerebral small vessel disease; EC, endothelial cell; ECD, extracellular domain; ECM, extracellular matrix; EGFR, epidermal growth factor-like repeat; GLA, α galactosidase A; GOM, granular osmiophilic material; HCHWA, Hereditary Cerebral Hemorrhage With Amyloidosis; HTRA, high temperature requirement factor A; PADMAL, pontine autosomal dominant microangiopathy, and leukoencephalopathy; RVCL-S, retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestation; VSMC, vascular smooth muscle cell; and WMH, white matter hyperintensity.

targets, including activation of microglia[73,74] and blockade of oligodendrocyte replacement.[75]

Not all investigations support a role for BBB breakdown in CSVD. There was little evidence of BBB breakdown in neuropathological investigations of general CSVD[76] or in CADASIL pathological samples[77] and preclinical models.[78] Nonetheless, a causal role of BBB impairment deserves further investigation.

Attenuation of Regional Cerebral Vasoreactivity

The brain vasculature features an autoregulatory system that couples flow to demand at a microscopic level. Impaired activity-related changes in flow may selectively stress regions of metabolic demand, resulting in chronic and intermittent hypoperfusion that may not be appreciated in bulk CBF investigations.

Sam et al[79] reported decreased cerebrovascular reactivity in regional patterns that correlated with abnormal diffusion and perfusion patterns. Importantly, in longitudinal analysis, areas of loss of cerebrovascular reactivity developed white matter hyperintensities at 1-year follow-up.[80,81] Furthermore, Blair et al[82] described decreased vascular reactivity in CSVD as assessed by MRI BOLD during a hypercapnic challenge that was related to the burden of white matter hyperintensities.

In CADASIL, Chabriat et al[55] did not observe decreases in vasoreactivity in normal-appearing white matter, although blood flow and reactivity were decreased in areas of white matter hyperintensity. But Liem et al[83] described a cohort of CADASIL subjects with decreased reactivity to acetazolamide that correlated with worsening of white matter hyperintensities 7 years later. Although total CBF was decreased in this CADASIL cohort, unlike reactivity, it did not correspond with radiological worsening. Separately, arterial spin labeling demonstrated impaired vascular reactivity in CADASIL in response to visual and motor stimulation,[84] with unimpaired evoked potentials.

In CADASIL animal models of CSVD, arteriolar vasoreactivity to chemical stimulation of downstream

endothelial cells or to whisker stimulation is impaired via attenuation of an endothelial inward rectifying potassium channel Kir2.1. Features upstream of Kir2.1 impairment, including TIMP3-mediated suppression of epidermal growth factor signaling, implicate a potential comprehensive pathological pathway to CSVD.[85]

Other Pathways to Dementia

A role for pathology of oligodendrocytes has also been investigated, although these sites of injury are likely downstream from the initiating vascular problem.[86,87] In line with this, oligodendrocyte precursor cell progression, which is thought to aid in repair of white matter injury, has been shown to be inhibited by endothelial damage in cathepsin A-related arteriopathy.[88]

WHAT ARE THE CORE RECOMMENDATIONS FOR THE MANAGEMENT OF CSVD DEMENTIA?

Antihypertensives

Treating hypertension prevents first and recurrent stroke, and, as the SPRINT trial (Systolic Blood Pressure Intervention Trial) demonstrated, intensive blood pressure targets reduced fatal and non-fatal cardiovascular events and all-cause mortality.[89] Meta-analyses of randomized trials of antihypertensive treatments found that antihypertensive treatment reduces white matter hyperintensities, and more intensive therapy is more effective.[90,91]

However, evidence for intensive blood pressure control having a beneficial effect on cognitive outcomes (cognitive decline, mild cognitive impairment, or dementia) is not certain. SPRINT found that intensive blood pressure control reduced the incidence of mild cognitive impairment but did not significantly reduce risk of dementia.[92] A SPRINT substudy did not show benefit from intensive therapy on memory or speed of mental processing.[93] This lack of clear benefit on dementia, memory, or speed of mental processing is particularly disappointing because SPRINT found favorable effects of intensive blood pressure lowering on white matter disease, whole brain volume, and CBF (Table 2). A meta-analysis involving over seventeen thousand patients found no association of lower versus standard blood pressure targets with incidence of cognitive decline, mild cognitive impairment, and dementia.[98] It is possible that the neutral results from intensive blood pressure trials are the product of intervening later in life and not following patients long enough to detect treatment group curve separation.

Although blood pressure lowering has been shown to improve radiographic and physiological parameters, on balance one cannot currently conclude that intensive pharmacological blood pressure lowering definitively protects patients from dementia. However, there does not appear to be cognitive harm from lowering blood pressure. Elderly patients are at greatest risk of incident cognitive impairment and dementia, and older patients show the same relative risk reduction of cardiovascular events as younger patients from pharmacological lowering of blood pressure.[99]

Antiplatelet Therapy

Antiplatelet therapy has been studied extensively in patients with ischemic strokes due to CSVD. A meta-analysis of seventeen trials found that single antiplatelet therapy effectively reduces risk of recurrent stroke in patients with recent small subcortical infarct.[100] However, the SPS3 trial (Secondary Prevention of Small Subcortical Strokes Trial) found that dual antiplatelet therapy with aspirin and clopidogrel doubled risk of bleeding without lowering the risk of recurrent stroke.[101] Much less is known about the effects of antiplatelets on dementia associated with CSVD.

Table 3 proposes how to manage antiplatelet therapies in patients with cognitive impairment based on clinical and imaging characteristics. Patients without recent small subcortical infarct who are found to have signs of CSVD either incidentally (eg, for evaluation of headache) or during evaluation of mild cognitive impairment or dementia probably ought not be prescribed aspirin unless they have manifest atherosclerotic disease. A series of recent randomized trials do not support aspirin for primary prevention in several adult populations without manifesting atherosclerosis.[102] Also, when the timing of occurrence of a radiographically detected lacune is unknown (asymptomatic and not diffusion-weighted imaging+), aspirin may well be of no benefit in reducing recurrence. A meta-analysis of secondary prevention trials showed that benefits in reducing recurrent stroke seen before 12 weeks of stroke onset were no longer evident beyond 12 weeks.[103] To add further concern about broad use of antiplatelets for CSVD, microbleeds are a marker of risk of hemorrhagic stroke in patients taking aspirin, and meta-analysis of 37 observational studies showed that antiplatelet therapy increases the risk of lobar CMBs and intracranial hemorrhage.[104]

Statins

A meta-analysis of studies through 2017, found that use of statins reduces the risk of all-type dementia, mild cognitive impairment, and AD.[105] Interestingly, statin use did not significantly lower the risk of vascular dementia.[105] Ott et al analyzed the literature up to 2015 and suggested that fears that statins impair cognition appear unfounded.[106]

Table 2. Lessons From SPRINT Trial and SPRINT-MIND Substudy

Clinical outcomes	
Wright et al[89]	Intensive BP therapy did not reduce risk of stroke but did reduce all-cause mortality by 27%.
Williamson et al[92]	Intensive BP group had a significantly reduced risk of MCI and composite end point of MCI and dementia compared to standard group.
Rapp et al[94]	No clinically significant difference was observed between intensive and standard treatment groups for memory or processing speed.
Radiographic and physiological outcomes	
Nasrallah et al[95]	Intensive BP group had 0.54 cm^3 less increase in white matter lesion volume than the standard group over a median follow-up of 3.40 years.
Goldstein et al[96]	SPRINT-MIND post hoc analysis showed that use of ACE inhibitors was most consistently associated with decreased white matter progression.
Nasrallah et al[95]	Intensive BP group had 3.7 cm^3 less total brain volume loss than standard BP group.
Dolui et al[97]	Intensive BP group had 2.30 mL/100 g/min higher whole brain perfusion change than standard BP group.

Target for intensive systolic BP control was <120 mm Hg and for standard systolic BP control <140 mm Hg. ACE indicates angiotensin-converting enzyme; BP, blood pressure; MCI, mild cognitive impairment; SPRINT, Systolic Blood Pressure Intervention Trial; and SPRINT-MIND, Systolic Blood Pressure Intervention Trial - Memory and Cognition in Decreased Hypertension.

Although trial data are limited, statins appear to reduce new silent infarcts and reduce white matter hyperintensities.[107] Statins have no appreciable effect on microbleeds overall but may increase risk of lobar bleeds.[108] Interestingly, a 2×2 factorial trial of telmisartan and low-dose rosuvastatin in elderly hypertensive individuals found that rosuvastatin lowered the incidence of Fazekas ≥2 white matter changes and that there was a favorable interaction with telmisartan.[109] At this point, it is appropriate to use statins in accordance with primary and secondary guidelines for prevention of cardiovascular and cerebrovascular disease.[110]

Diabetes Control

Randomized trials have shown that intensive glycemic control in patients with diabetes reduces risk of microvascular complications (neuropathy, nephropathy, and retinopathy) but has not been shown to reduce risk of impaired memory or cognitive function.[111] There is limited evidence for intensive glycemic control preserving small vessel function. However, diabetes is not a contraindication to tight blood pressure control. Secondary analysis of the ACCORD MIND trial (Action to Control Cardiovasular Risk in Diabetes - Memory in Diabetes) showed that in patients with type 2 diabetes tight blood pressure control reduced progression in white matter hyperintensities.[112]

Cholinesterase Inhibitors

Many patients with vascular cognitive impairment will have CSVD. Cholinesterase inhibitors have demonstrated modest significant benefits in cognition in patients with vascular dementia.[113] However, this modest benefit comes at a cost of side effects that may include dizziness, nausea, vomiting, and diarrhea. If the patient is willing to accept the risks, a therapeutic trial is reasonable, but if clinically significant benefits are not observed within 3 months, the medication should be discontinued.

CONCLUSIONS AND FUTURE DIRECTIONS

CSVD has attracted significant attention due to its high prevalence, impact on neurological health, and clear role in dementia. Several features of CSVD-related dementia have been highlighted: (1) CSVD-related dementia is a group of heterogenous pathologies that currently depend on MRI imaging for diagnosis; (2) CSVD is not deterministic of cognitive impairment but is an important risk factor for dementia; (3) CSVD-related dementia very

Table 3. Use of Antiplatelet Therapy in Patients With MCI or Dementia and CSVD

	Recent small subcortical infarct	Lacune of presumed vascular origin with symptomatic atherosclerosis	Lacune of presumed vascular origin without symptomatic atherosclerosis	Lacune of presumed vascular origin with >5–10 CMBs and no symptomatic atherosclerosis	CSVD without lacunes, with symptomatic atherosclerosis	CSVD without lacunes, without symptomatic atherosclerosis
Indicated	SAPT and DAPT	SAPT			SAPT	
Possibly indicated			SAPT			SAPT
Contraindicated		DAPT	DAPT	SAPT and DAPT	DAPT	DAPT

CMB denotes cerebral microbleeds; CSVD, cerebral small vessel disease; DAPT, dual antiplatelet therapy; MCI, mild cognitive impairment; and SAPT, single antiplatelet therapy.

often co-exists with other neurodegenerative conditions that are obscure its recognition; (4) CSVD may cause brain injury via physiological mechanisms which extend beyond simple blood flow reduction; (5) monogenic forms of CSVD dementia have been described and promise to provide important footholds to understand mechanisms of disease; and (6) emerging evidence indicates that wisely selected cardiovascular medications could modify disease. Many of these features have been supported by recent work, but none are definitive; what is more certain is that rigorous investigations are still needed, particularly with respect to establishing robust, standardized disease markers that enable refinement of natural history, mechanistic, and therapeutic studies.

ARTICLE INFORMATION

Affiliations

Departments of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY (F.M.E.). Neurology Service, VA Bronx Healthcare System, NY (F.M.E.). Departments of Neurology and Molecular and Integrative Physiology, University of Michigan, Ann Arbor (M.M.W.). Neurology Service, VA Ann Arbor Healthcare System, MI (M.M.W.). Department of Neurology, Mayo Clinic, Jacksonville, FL (J.F.M.).

Acknowledgments

We thank Soo Jung Lee for histology and preparation of images.

Sources of Funding

Dr Elahi receives support from the Department of Veterans Affairs and the National Institute of Aging (IK2CX002180), Larry L. Hillblom Foundation (2019A012SUP), and New Vision Research. Dr Wang is supported by grants from the Department of Veterans Affairs (BX003824) and the National Institutes of Health (NIH; NS099160). He has also received support from Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) Together We Have Hope. Dr Meschia is supported by grants from the National Institute of Neurological Disorders and Stroke for the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2 [Carotid Revascularization Endarterectomy Versus Stenting Trial]; U01NS080168); CREST-2-Hemodynamics (CREST-H [Carotid Revascularization Endarterectomy Versus Stenting Trial - Hemodynamics]; R01NS097876); the Long-term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial (C2LOE; U01 NS119169); and the DISCOVERY Recruitment and Retention Core (DISCOVERY RRC; U19NS115388).

Disclosures

Dr Meschia reports compensation from National Institutes of Health (NIH) for data and safety monitoring services. The other authors report no conflicts.

REFERENCES

1. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12:822–838. doi: 10.1016/S1474-4422(13)70124-8
2. Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, Korvenoja A, Rueckert D, Barkhof F, Scheltens P, et al. Global burden of small vessel disease-related brain changes on mri predicts cognitive and functional decline. *Stroke.* 2020;51:170–178. doi: 10.1161/STROKEAHA.119.026170
3. Bown CW, Carare RO, Schrag MS, Jefferson AL. Physiology and clinical relevance of enlarged perivascular spaces in the aging brain. *Neurology.* 2022;98:107–117. doi: 10.1212/WNL.0000000000013077
4. Maillard P, Fletcher E, Singh B, Martinez O, Johnson DK, Olichney JM, Farias ST, DeCarli C. Cerebral white matter free water: a sensitive biomarker of cognition and function. *Neurology.* 2019;92:e2221–e2231. doi: 10.1212/WNL.0000000000007449
5. Raja R, Rosenberg GA, Caprihan A. MRI measurements of Blood-Brain Barrier function in dementia: a review of recent studies. *Neuropharmacology.* 2018;134:259–271. doi: 10.1016/j.neuropharm.2017.10.034
6. Pohjasvaara T, Mäntylä R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. *Stroke.* 2000;31:2952–2957. doi: 10.1161/01.str.31.12.2952
7. Gold G, Bouras C, Canuto A, Bergallo MF, Herrmann FR, Hof PR, Mayor PA, Michel JP, Giannakopoulos P. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. *Am J Psychiatry.* 2002;159:82–87. doi: 10.1176/appi.ajp.159.1.82
8. McAleese KE, Alafuzoff I, Charidimou A, De Reuck J, Grinberg LT, Hainsworth AH, Hortobagyi T, Ince P, Jellinger K, Gao J, et al. Post-mortem assessment in vascular dementia: advances and aspirations. *BMC Med.* 2016;14:129. doi: 10.1186/s12916-016-0676-5
9. Humphreys CA, Jansen MA, Muñoz Maniega S, González-Castro V, Pernet C, Deary IJ, Al-Shahi Salman R, Wardlaw JM, Smith C. A protocol for precise comparisons of small vessel disease lesions between ex vivo magnetic resonance imaging and histopathology. *Int J Stroke.* 2019;14:310–320. doi: 10.1177/1747493018799962
10. Kaffashian S, Soumaré A, Zhu YC, Mazoyer B, Debette S, Tzourio C. Long-term clinical impact of vascular brain lesions on magnetic resonance imaging in older adults in the population. *Stroke.* 2016;47:2865–2869. doi: 10.1161/STROKEAHA.116.014695
11. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA, Seshadri S. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham offspring study. *Stroke.* 2010;41:600–606. doi: 10.1161/STROKEAHA.109.570044
12. Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, Fitzpatrick A, Fried L, Haan MN. Risk factors for dementia in the cardiovascular health cognition study. *Neuroepidemiology.* 2003;22:13–22. doi: 10.1159/000067109
13. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Cerebral white matter lesions and the risk of dementia. *Arch Neurol.* 2004;61:1531–1534. doi: 10.1001/archneur.61.10.1531
14. Bombois S, Debette S, Bruandet A, Delbeuck X, Delmaire C, Leys D, Pasquier F. Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. *Stroke.* 2008;39:2046–2051. doi: 10.1161/STROKEAHA.107.505206
15. Eckerström C, Olsson E, Klasson N, Berge J, Nordlund A, Bjerke M, Wallin A. Multimodal prediction of dementia with up to 10 years follow up: the Gothenburg MCI study. *J Alzheimers Dis.* 2015;44:205–214. doi: 10.3233/JAD-141053
16. Firbank MJ, Burton EJ, Barber R, Stephens S, Kenny RA, Ballard C, Kalaria RN, O'Brien JT. Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. *Neurobiol Aging.* 2007;28:1664–1669. doi: 10.1016/j.neurobiolaging.2006.07.009
17. Geroldi C, Rossi R, Calvagna C, Testa C, Bresciani L, Binetti G, Zanetti O, Frisoni GB. Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. *J Neurol Neurosurg Psychiatry.* 2006;77:1219–1222. doi: 10.1136/jnnp.2005.082651
18. Jokinen H, Kalska H, Ylikoski R, Madureira S, Verdelho A, van der Flier WM, Scheltens P, Barkhof F, Visser MC, Fazekas F, et al; LADIS group. Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study. *Cerebrovasc Dis.* 2009;27:384–391. doi: 10.1159/000207442
19. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O'Brien PC, Petersen RC, et al. Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. *Neurology.* 2009;72:1519–1525. doi: 10.1212/WNL.0b013e3181a2e864
20. Kim S, Choi SH, Lee YM, Kim MJ, Kim YD, Kim JY, Park JH, Myung W, Na HR, Han HJ, et al. Periventricular white matter hyperintensities and the risk of dementia: a CREDOS study. *Int Psychogeriatr.* 2015;27:2069–2077. doi: 10.1017/S1041610215001076
21. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, Tanzi RE, Albert MS, Greenberg SM, Guttmann CR. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. *Arch Neurol.* 2008;65:94–100. doi: 10.1001/archneurol.2007.23

22. Debette S, Schilling S, Duperron MG, Larsson SC, Markus HS. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. *JAMA Neurol.* 2019;76:81–94. doi: 10.1001/jamaneurol.2018.3122
23. Rensma SP, van Sloten TT, Launer LJ, Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: a systematic review and meta-analysis. *Neurosci Biobehav Rev.* 2018;90:164–173. doi: 10.1016/j.neubiorev.2018.04.003
24. Bos D, Wolters FJ, Darweesh SKL, Vernooij MW, de Wolf F, Ikram MA, Hofman A. Cerebral small vessel disease and the risk of dementia: a systematic review and meta-analysis of population-based evidence. *Alzheimers Dement.* 2018;14:1482–1492. doi: 10.1016/j.jalz.2018.04.007
25. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJ. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. *J Neurol Neurosurg Psychiatry.* 2011;82:126–135. doi: 10.1136/jnnp.2009.204685
26. Zhu YC, Dufouil C, Soumaré A, Mazoyer B, Chabriat H, Tzourio C. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. *J Alzheimers Dis.* 2010;22:663–672. doi: 10.3233/JAD-2010-100378
27. Ding J, Sigurðsson S, Jónsson PV, Eiriksdottir G, Charidimou A, Lopez OL, van Buchem MA, Guðnason V, Launer LJ. Large perivascular spaces visible on magnetic resonance imaging, cerebral small vessel disease progression, and risk of dementia: the age, gene/environment susceptibility-reykjavik study. *JAMA Neurol.* 2017;74:1105–1112. doi: 10.1001/jamaneurol.2017.1397
28. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al; Contributors. NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018
29. Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. *Nat Rev Neurol.* 2017;13:457–476. doi: 10.1038/nrneurol.2017.96
30. Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis SM, Deal JA, McKhann GM, Mosley TH, Sharrett AR, et al. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. *JAMA Neurol.* 2017;74:1246–1254. doi: 10.1001/jamaneurol.2017.1658
31. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. *Ann Neurol.* 2009;66:200–208. doi: 10.1002/ana.21706
32. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. *J Neuropathol Exp Neurol.* 2003;62:1287–1301. doi: 10.1093/jnen/62.12.1287
33. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet.* 2020;396:413–446. doi: 10.1016/S0140-6736(20)30367-6
34. Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. *Neuron.* 2017;96:17–42. doi: 10.1016/j.neuron.2017.07.030
35. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MC. CADASIL. *Lancet Neurol.* 2009;8:643–653. doi: 10.1016/S1474-4422(09)70127-9
36. Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Shungu DC, Naini AB, Mohr JP. CADASIL in a North American family: clinical, pathologic, and radiologic findings. *Neurology.* 1998;51:844–849. doi: 10.1212/wnl.51.3.844
37. Rutten JW, Hack RJ, Duering M, Gravesteijn G, Dauwerse JG, Overzier M, van den Akker EB, Slagboom E, Holstege H, Nho K, et al. Broad phenotype of cysteine-altering. *Neurology.* 2020;95:e1835–e1843. doi: 10.1212/WNL.0000000000010525
38. Sassi C, Nalls MA, Ridge PG, Gibbs JR, Lupton MK, Troakes C, Lunnon K, Al-Sarraj S, Brown KS, Medway C, et al. Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. *Neurobiol Aging.* 2018;66:179.e17179.e117–179.e171179.e29. doi: 10.1016/j.neurobiolaging.2018.01.015
39. Ramirez J, Dilliott AA, Binns MA, Breen DP, Evans EC, Beaton D, McLaughlin PM, Kwan D, Holmes MF, Ozzoude M, et al; Ontario Neurodegenerative Disease Research Initiative Investigators. Parkinson's disease, NOTCH3 genetic variants, and white matter hyperintensities. *Mov Disord.* 2020;35:2090–2095. doi: 10.1002/mds.28171
40. Rutten JW, Dauwerse HG, Gravesteijn G, van Belzen MJ, van der Grond J, Polke JM, Bernal-Quiros M, Lesnik Oberstein SA. Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL. *Ann Clin Transl Neurol.* 2016;3:844–853. doi: 10.1002/acn3.344
41. Cho BPH, Nannoni S, Harshfield EL, Tozer D, Gräf S, Bell S, Markus HS. variants are more common than expected in the general population and associated with stroke and vascular dementia: an analysis of 200 000 participants. *J Neurol Neurosurg Psychiatry.* 2021;92:694–701. doi: 10.1136/jnnp-2020-325838
42. Bisschops RH, van der Graaf Y, Mali WP, van der Grond J, group S. High total cerebral blood flow is associated with a decrease of white matter lesions. *J Neurol.* 2004;251:1481–1485. doi: 10.1007/s00415-004-0569-y
43. van Es AC, van der Grond J, ten Dam VH, de Craen AJ, Blauw GJ, Westendorp RG, Admiraal-Behloul F, van Buchem MA, Group PS. Associations between total cerebral blood flow and age related changes of the brain. *PLoS One.* 2010;5:e9825. doi: 10.1371/journal.pone.0009825
44. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Vrooman HA, Hofman A, Krestin GP, Breteler MM. Total cerebral blood flow and total brain perfusion in the general population: the Rotterdam Scan Study. *J Cereb Blood Flow Metab.* 2008;28:412–419. doi: 10.1038/sj.jcbfm.9600526
45. Crane DE, Black SE, Ganda A, Mikulis DJ, Nestor SM, Donahue MJ, MacIntosh BJ. Gray matter blood flow and volume are reduced in association with white matter hyperintensity lesion burden: a cross-sectional MRI study. *Front Aging Neurosci.* 2015;7:131. doi: 10.3389/fnagi.2015.00131
46. Heliopoulos I, Artemis D, Vadikolias K, Tripsianis G, Piperidou C, Tsivgoulis G. Association of ultrasonographic parameters with subclinical white-matter hyperintensities in hypertensive patients. *Cardiovasc Psychiatry Neurol.* 2012;2012:616572. doi: 10.1155/2012/616572
47. Tzourio C, Lévy C, Dufouil C, Touboul PJ, Ducimetière P, Alpérovitch A. Low cerebral blood flow velocity and risk of white matter hyperintensities. *Ann Neurol.* 2001;49:411–414. doi: 10.1002/ana.82
48. Alosco ML, Brickman AM, Spitznagel MB, Garcia SL, Narkhede A, Griffith EY, Raz N, Cohen R, Sweet LH, Colbert LH, et al. Cerebral perfusion is associated with white matter hyperintensities in older adults with heart failure. *Congest Heart Fail.* 2013;19:E29–E34. doi: 10.1111/chf.12025
49. Shi Y, Thrippleton MJ, Makin SD, Marshall I, Geerlings MI, de Craen AJM, van Buchem MA, Wardlaw JM. Cerebral blood flow in small vessel disease: a systematic review and meta-analysis. *J Cereb Blood Flow Metab.* 2016;36:1653–1667. doi: 10.1177/0271678X16662891
50. Ott BR, Faberman RS, Noto RB, Rogg JM, Hough TJ, Tung GA, Spencer PK. A SPECT imaging study of MRI white matter hyperintensity in patients with degenerative dementia. *Dement Geriatr Cogn Disord.* 1997;8:348–354. doi: 10.1159/000106654
51. Claus JJ, Breteler MM, Hasan D, Krenning EP, Bots ML, Grobbee DE, van Swieten JC, van Harskamp F, Hofman A. Vascular risk factors, atherosclerosis, cerebral white matter lesions and cerebral perfusion in a population-based study. *Eur J Nucl Med.* 1996;23:675–682. doi: 10.1007/BF00834530
52. Nylander R, Fahlström M, Rostrup E, Kullberg J, Damangir S, Ahlström H, Lind L, Larsson EM. Quantitative and qualitative MRI evaluation of cerebral small vessel disease in an elderly population: a longitudinal study. *Acta Radiol* 2018;59:612–618. doi: 10.1177/0284185117727567
53. Promjunyakul NO, Dodge HH, Lahna D, Boespflug EL, Kaye JA, Rooney WD, Silbert LC. Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time. *Neurology.* 2018;90:e2119–e2126. doi: 10.1212/WNL.0000000000005684
54. van der Veen PH, Muller M, Vincken KL, Hendrikse J, Mali WP, van der Graaf Y, Geerlings MI, Group SS. Longitudinal relationship between cerebral small-vessel disease and cerebral blood flow: the second manifestations of arterial disease-magnetic resonance study. *Stroke.* 2015;46:1233–1238. doi: 10.1161/STROKEAHA.114.008030
55. Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K, Jobert A, Le Bihan D, Bousser MG. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. *Stroke.* 2000;31:1904–1912. doi: 10.1161/01.str.31.8.1904
56. Østergaard L, Engedal TS, Moreton F, Hansen MB, Wardlaw JM, Dalkara T, Markus HS, Muir KW. Cerebral small vessel disease: capillary pathways to stroke and cognitive decline. *J Cereb Blood Flow Metab.* 2016;36:302–325. doi: 10.1177/0271678X15606723
57. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, et al; MRC Cognitive Function and Ageing Neuropathology Study Group. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. *Stroke.* 2006;37:1391–1398. doi: 10.1161/01.STR.0000221308.94473.14
58. Tomimoto H, Akiguchi I, Suenaga T, Nishimura M, Wakita H, Nakamura S, Kimura J. Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. *Stroke.* 1996;27:2069–2074. doi: 10.1161/01.str.27.11.2069

59. Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU, Ghebremedhin E, Thal DR. Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. *J Neuropathol Exp Neurol.* 2008;67:842–856. doi: 10.1097/NEN.0b013e3181836a71
60. Akiguchi I, Tomimoto H, Suenaga T, Wakita H, Budka H. Blood-brain barrier dysfunction in Binswanger's disease; an immunohistochemical study. *Acta Neuropathol.* 1998;95:78–84. doi: 10.1007/s004010050768
61. Zhang X, Meng H, Blaivas M, Rushing EJ, Moore BE, Schwartz J, Lopes MB, Worrall BB, Wang MM. Von Willebrand Factor permeates small vessels in CADASIL and inhibits smooth muscle gene expression. *Transl Stroke Res.* 2012;3:138–145. doi: 10.1007/s12975-011-0112-2
62. Simpson JE, Wharton SB, Cooper J, Gelsthorpe C, Baxter L, Forster G, Shaw PJ, Savva G, Matthews FE, Brayne C, et al. Alterations of the blood-brain barrier in cerebral white matter lesions in the ageing brain. *Neurosci Lett.* 2010;486:246–251. doi: 10.1016/j.neulet.2010.09.063
63. Young VG, Halliday GM, Kril JJ. Neuropathologic correlates of white matter hyperintensities. *Neurology.* 2008;71:804–811. doi: 10.1212/01.wnl.0000319691.50117.54
64. Ghosh M, Balbi M, Hellal F, Dichgans M, Lindauer U, Plesnila N. Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. *Ann Neurol.* 2015;78:887–900. doi: 10.1002/ana.24512
65. Taheri S, Gasparovic C, Huisa BN, Adair JC, Edmonds E, Prestopnik J, Grossetete M, Shah NJ, Wills J, Qualls C, et al. Blood-brain barrier permeability abnormalities in vascular cognitive impairment. *Stroke.* 2011;42:2158–2163. doi: 10.1161/STROKEAHA.110.611731
66. Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. *J Neurol Neurosurg Psychiatry.* 2010;81:192–197. doi: 10.1136/jnnp.2009.172072
67. Wardlaw JM, Doubal FN, Valdes-Hernandez M, Wang X, Chappell FM, Shuler K, Armitage PA, Carpenter TC, Dennis MS. Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease. *Stroke.* 2013;44:525–527. doi: 10.1161/STROKEAHA.112.669994
68. Li Y, Li M, Zuo L, Shi Q, Qin W, Yang L, Jiang T, Hu W. Compromised blood-brain barrier integrity is associated with total magnetic resonance imaging burden of cerebral small vessel disease. *Front Neurol.* 2018;9:221. doi: 10.3389/fneur.2018.00221
69. Zhang CE, Wong SM, Uiterwijk R, Backes WH, Jansen JFA, Jeukens CRLP, van Oostenbrugge RJ, Staals J. Blood-brain barrier leakage in relation to white matter hyperintensity volume and cognition in small vessel disease and normal aging. *Brain Imaging Behav.* 2019;13:389–395. doi: 10.1007/s11682-018-9855-7
70. Muñoz Maniega S, Chappell FM, Valdés Hernández MC, Armitage PA, Makin SD, Heye AK, Thrippleton MJ, Sakka E, Shuler K, Dennis MS, et al. Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease. *J Cereb Blood Flow Metab.* 2017;37:644–656. doi: 10.1177/0271678X16635657
71. Huisa BN, Caprihan A, Thompson J, Prestopnik J, Qualls CR, Rosenberg GA. Long-term blood-brain barrier permeability changes in binswanger disease. *Stroke.* 2015;46:2413–2418. doi: 10.1161/STROKEAHA.115.009589
72. Wardlaw JM, Makin SJ, Valdés Hernández MC, Armitage PA, Heye AK, Chappell FM, Muñoz-Maniega S, Sakka E, Shuler K, Dennis MS, et al. Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study. *Alzheimer's Dement.* 2017;13:634–643. doi: 10.1016/j.jalz.2016.09.006
73. Merlini M, Rafalski VA, Rios Coronado PE, Gill TM, Ellisman M, Muthukumar G, Subramanian KS, Ryu JK, Syme CA, Davalos D, et al. Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an alzheimer's disease model. *Neuron.* 2019;101:1099–1108.e6. doi: 10.1016/j.neuron.2019.01.014
74. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. *J Cell Mol Med.* 2009;13:2911–2925. doi: 10.1111/j.1582-4934.2008.00434.x
75. Petersen MA, Ryu JK, Chang KJ, Etxeberria A, Bardehle S, Mendiola AS, Kamau-Devers W, Fancy SPJ, Thor A, Bushong EA, et al. Fibrinogen activates bmp signaling in oligodendrocyte progenitor cells and inhibits remyelination after vascular damage. *Neuron.* 2017;96:1003–1012.e7. doi: 10.1016/j.neuron.2017.10.008
76. Hainsworth AH, Oommen AT, Bridges LR. Endothelial cells and human cerebral small vessel disease. *Brain Pathol.* 2015;25:44–50. doi: 10.1111/bpa.12224
77. Rajani RM, Ratelade J, Domenga-Denier V, Hase Y, Kalimo H, Kalaria RN, Joutel A. Blood brain barrier leakage is not a consistent feature of white matter lesions in CADASIL. *Acta Neuropathol Commun.* 2019;7:187. doi: 10.1186/s40478-019-0844-x
78. Joutel A, Monet-Leprêtre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S, Lemaire-Carrette B, Domenga V, Schedl A, Lacombe P, et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. *J Clin Invest.* 2010;120:433–445. doi: 10.1172/JCI39733
79. Sam K, Peltenburg B, Conklin J, Sobczyk O, Poublanc J, Crawley AP, Mandell DM, Venkatraghavan L, Duffin J, Fisher JA, et al. Cerebrovascular reactivity and white matter integrity. *Neurology.* 2016;87:2333–2339. doi: 10.1212/WNL.0000000000003373
80. Sam K, Crawley AP, Conklin J, Poublanc J, Sobczyk O, Mandell DM, Venkatraghavan L, Duffin J, Fisher JA, Black SE, et al. Development of white matter hyperintensity is preceded by reduced cerebrovascular reactivity. *Ann Neurol.* 2016;80:277–285. doi: 10.1002/ana.24712
81. Sam K, Conklin J, Holmes KR, Sobczyk O, Poublanc J, Crawley AP, Mandell DM, Venkatraghavan L, Duffin J, Fisher JA, et al. Impaired dynamic cerebrovascular response to hypercapnia predicts development of white matter hyperintensities. *Neuroimage Clin.* 2016;11:796–801. doi: 10.1016/j.nicl.2016.05.008
82. Blair GW, Thrippleton MJ, Shi Y, Hamilton I, Stringer M, Chappell F, Dickie DA, Andrews P, Marshall I, Doubal FN, et al. Intracranial hemodynamic relationships in patients with cerebral small vessel disease. *Neurology.* 2020;94:e2258–e2269. doi: 10.1212/WNL.0000000000009483
83. Liem MK, Lesnik Oberstein SA, Haan J, Boom R, Ferrari MD, Buchem MA, Grond J. Cerebrovascular reactivity is a main determinant of white matter hyperintensity progression in CADASIL. *AJNR Am J Neuroradiol.* 2009;30:1244–1247. doi: 10.3174/ajnr.a1533
84. Huneau C, Houot M, Joutel A, Béranger B, Giroux C, Benali H, Chabriat H. Altered dynamics of neurovascular coupling in CADASIL. *Ann Clin Transl Neurol.* 2018;5:788–802. doi: 10.1002/acn3.574
85. Dabertrand F, Harraz OF, Koide M, Longden TA, Rosehart AC, Hill-Eubanks DC, Joutel A, Nelson MT. PIP2 corrects cerebral blood flow deficits in small vessel disease by rescuing capillary Kir2.1 activity. *Proc Natl Acad Sci U S A.* 2021;118:e2025998118. doi: 10.1073/pnas.2025998118
86. Rajani RM, Williams A. Endothelial cell-oligodendrocyte interactions in small vessel disease and aging. *Clin Sci (Lond).* 2017;131:369–379. doi: 10.1042/CS20160618
87. Joutel A, Chabriat H. Pathogenesis of white matter changes in cerebral small vessel diseases: beyond vessel-intrinsic mechanisms. *Clin Sci (Lond).* 2017;131:635–651. doi: 10.1042/CS20160380
88. Bugiani M, Kevelam SH, Bakels HS, Waisfisz Q, Ceuterick-de Groote C, Niessen HW, Abbink TE, Lesnik Oberstein SA, van der Knaap MS. Cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL). *Neurology.* 2016;87:1777–1786. doi: 10.1212/WNL.0000000000003251
89. Wright JT, Whelton PK, Johnson KC, Snyder JK, Reboussin DM, Cushman WC, Williamson JD, Pajewski NM, Cheung AK, Lewis CE, et al; SPRINT Research Group. SPRINT revisited: updated results and implications. *Hypertension.* 2021;78:1701–1710. doi: 10.1161/HYPERTENSIONAHA.121.17682
90. Su C, Wu H, Yang X, Zhao B, Zhao R. The relation between antihypertensive treatment and progression of cerebral small vessel disease: a systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltim).* 2021;100:e26749. doi: 10.1097/MD.0000000000026749
91. Lai Y, Jiang C, Du X, Sang C, Guo X, Bai R, Tang R, Dong J, Ma C. Effect of intensive blood pressure control on the prevention of white matter hyperintensity: Systematic review and meta-analysis of randomized trials. *J Clin Hypertens (Greenwich).* 2020;22:1968–1973. doi: 10.1111/jch.14030
92. Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, et al; SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. *JAMA.* 2019;321:553–561. doi: 10.1001/jama.2018.21442
93. Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, Benavente OR, Investigators S. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. *Lancet Neurol.* 2014;13:1177–1185. doi: 10.1016/S1474-4422(14)70224-8
94. Rapp SR, Gaussoin SA, Sachs BC, Chelune G, Supiano MA, Lerner AJ, Wadley VG, Wilson VM, Fine LJ, Whittle JC, et al; SPRINT Research Group. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial. *Lancet Neurol.* 2020;19:899–907. doi: 10.1016/S1474-4422(20)30319-7

95. Nasrallah IM, Pajewski NM, Auchus AP, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, et al; SPRINT MIND Investigators for the SPRINT Research Group. Association of intensive vs standard blood pressure control with cerebral white matter lesions. *JAMA.* 2019;322:524–534. doi: 10.1001/jama.2019.10551
96. Goldstein ED, Wolcott Z, Garg G, Navarro K, Delic A, Yaghi S, Sederholm B, Prabhakaran S, Wong KH, McLean K, et al. Effect of antihypertensives by class on cerebral small vessel disease: a post hoc analysis of SPRINT-MIND. *Stroke.* 2022;53:2435–2440. doi: 10.1161/STROKEAHA.121.037997
97. Dolui S, Detre JA, Gaussoin SA, Herrick JS, Wang DJJ, Tamura MK, Cho ME, Haley WE, Launer LJ, Punzi HA, et al. Association of intensive vs standard blood pressure control with cerebral blood flow: secondary analysis of the SPRINT MIND Randomized Clinical Trial. *JAMA Neurol.* 2022;79:380–389. doi: 10.1001/jamaneurol.2022.0074
98. Dallaire-Théroux C, Quesnel-Olivo MH, Brochu K, Bergeron F, O'Connor S, Turgeon AF, Laforce RJ, Verreault S, Camden MC, Duchesne S. Evaluation of intensive vs standard blood pressure reduction and association with cognitive decline and dementia: a systematic review and meta-analysis. *JAMA Netw Open.* 2021;4:e2134553. doi: 10.1001/jamanetworkopen.2021.34553
99. Collaboration BPLTT. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. *Lancet.* 2021;398:1053–1064. doi: 10.1016/S0140-6736(21)01921-8
100. Kwok CS, Shoamanesh A, Copley HC, Myint PK, Loke YK, Benavente OR. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. *Stroke.* 2015;46:1014–1023. doi: 10.1161/STROKEAHA.114.008422
101. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM, Group SS. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. *Lancet.* 2013;382:507–515. doi: 10.1016/S0140-6736(13)60852-1
102. Marquis-Gravel G, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS. Revisiting the role of aspirin for the primary prevention of cardiovascular disease. *Circulation.* 2019;140:1115–1124. doi: 10.1161/CIRCULATIONAHA.119.040205
103. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. *Lancet.* 2016;388:365–375. doi: 10.1016/S0140-6736(16)30468-8
104. Qiu J, Ye H, Wang J, Yan J, Wang Y. Antiplatelet Therapy, Cerebral Microbleeds, and Intracerebral Hemorrhage: A Meta-Analysis. *Stroke.* 2018;49:1751–1754. doi: 10.1161/STROKEAHA.118.021789
105. Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ, Yang WC, Chen YW, Wu CK, Veronese N, et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. *Sci Rep.* 2018;8:5804. doi: 10.1038/s41598-018-24248-8
106. Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. *J Gen Intern Med.* 2015;30:348–358. doi: 10.1007/s11606-014-3115-3
107. Katsanos AH, Lioutas VA, Charidimou A, Catanese L, Ng KKH, Perera K, de Sa Boasquevisque D, Tsivgoulis G, Smith EE, Sharma M, et al. Statin treatment and accrual of covert cerebral ischaemia on neuroimaging: a systematic review and meta-analysis of randomized trials. *Eur J Neurol.* 2020;27:1023–1027. doi: 10.1111/ene.14196
108. Katsanos AH, Lioutas VA, Charidimou A, Catanese L, Ng KKH, Perera K, de Sa Boasquevisque D, Falcone GJ, Sheth KN, Romero JR, et al; International META-MICROBLEEDS Initiative. Statin treatment and cerebral microbleeds: A systematic review and meta-analysis. *J Neurol Sci.* 2021;420:117224. doi: 10.1016/j.jns.2020.117224
109. Zhang H, Cui Y, Zhao Y, Dong Y, Duan D, Wang J, Sheng L, Ji T, Zhou T, Hu W, et al. Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. *Hypertens Res.* 2019;42:717–729. doi: 10.1038/s41440-018-0165-7
110. Appleton JP, Scutt P, Sprigg N, Bath PM. Hypercholesterolaemia and vascular dementia. *Clin Sci (Lond).* 2017;131:1561–1578. doi: 10.1042/CS20160382
111. Crabtree T, Ogendo JJ, Vinogradova Y, Gordon J, Idris I. Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. *Expert Rev Endocrinol Metab.* 2022;17:255–267. doi: 10.1080/17446651.2022.2079495
112. de Havenon A, Majersik JJ, Tirschwell DL, McNally JS, Stoddard G, Rost NS. Blood pressure, glycemic control, and white matter hyperintensity progression in type 2 diabetics. *Neurology.* 2019;92:e1168–e1175. doi: 10.1212/WNL.0000000000007093
113. Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. *Cochrane Database Syst Rev.* 2021;2:CD013306. doi: 10.1002/14651858.CD013306.pub2